International journal of cardiology · 2025
Safety and efficacy of transcatheter aortic valve replacement using Sapien 3 balloon-expandable valve in type 0 bicuspid aortic valve stenosis patients.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Dejing, Wang Moyang, Wang Jian'an, Liu Xianbao, Wei Lai, Qiu Chunguang, Wu Leiming, Li Yi, Xu Kai, Zhang Junjie, Liu Yuhao, Wang Sheng, Zhu Dan, Zhou Yujie, Zhang Haibo, Yuan Yiqiang, Fang Zhenfei, Tang Yida, Wang Yan, Yang Yining, Luo Jianfang, Jiang Xiaofei, Ma Xiang, Jia Guoli, Chen Shenglong, Dai Min, Guo Yingqiang, Han Ke, Li Gang, Liu Jie, Wu Yanqing, Xu Li, Zhang Qi, Wu Yongjian
Аннотация
BACKGROUND: Data regarding the safety and efficacy of balloon expandable valves (BEVs) for transcatheter aortic valve replacement (TAVR) in patients with Sievers type 0 bicuspid aortic valve (BAV) stenosis remain limited.
AIMS: This study aims to evaluate the clinical outcomes of BEVs implantation in patients with Sievers type 0 BAV.
METHODS: We conducted a multicenter, retrospective study across 28 centers in China between October 2020 and March 2023. Consecutive patients with Sievers type 0 BAV anatomy undergoing TAVR with the Edwards Sapien 3 BEV were enrolled.
RESULTS: The study included 131 patients with Sievers type 0 BAV (mean age 69.8 ± 7.5 years; 52.7 % male). The lateral-lateral type predominated (86.3 %). Calcification distribution analysis identified the superior leaflet margin as the most primary site (62.6 %). All procedures utilized femoral artery access. High implantation depth (The ratio of the aortic side of the prosthetic valve to the outflow tract side is > 8:2) was achieved in 80.2 % of cases. Prosthetic valves smaller than 26 mm were implanted in nearly half of the patients (49.6 %). The 30-day all-cause mortality rate was 0.8 %, with no incidence of disabling stroke. The overall technical success rate was 98.5 %.
CONCLUSION: The findings of this study demonstrate that BEVs implantation in patients with Sievers type 0 BAV is associated with favorable safety and efficacy outcomes. These results provide valuable insights for current TAVR practice in this specific patient population.
AIMS: This study aims to evaluate the clinical outcomes of BEVs implantation in patients with Sievers type 0 BAV.
METHODS: We conducted a multicenter, retrospective study across 28 centers in China between October 2020 and March 2023. Consecutive patients with Sievers type 0 BAV anatomy undergoing TAVR with the Edwards Sapien 3 BEV were enrolled.
RESULTS: The study included 131 patients with Sievers type 0 BAV (mean age 69.8 ± 7.5 years; 52.7 % male). The lateral-lateral type predominated (86.3 %). Calcification distribution analysis identified the superior leaflet margin as the most primary site (62.6 %). All procedures utilized femoral artery access. High implantation depth (The ratio of the aortic side of the prosthetic valve to the outflow tract side is > 8:2) was achieved in 80.2 % of cases. Prosthetic valves smaller than 26 mm were implanted in nearly half of the patients (49.6 %). The 30-day all-cause mortality rate was 0.8 %, with no incidence of disabling stroke. The overall technical success rate was 98.5 %.
CONCLUSION: The findings of this study demonstrate that BEVs implantation in patients with Sievers type 0 BAV is associated with favorable safety and efficacy outcomes. These results provide valuable insights for current TAVR practice in this specific patient population.